Effect of ART 2 treatment on biochemical profile during treatment of second line ART
DOI:
https://doi.org/10.18203/2349-3933.ijam20201610Keywords:
AIDS, ART 2, HIVAbstract
Background: AIDS was the first recognized in U.S in summer of 1981 at centers for disease control and prevention reported the unexplained occurrence of pneumocystis jiroveci in previously healthy homosexual men in Los Angeles and Kaposi. First time in 1983 HIV syndrome was isolated from a patient of lymphadenopathy. Person with positive HIV serology who have ever had a CD4 lymphocyte count below 200celles/mcl and CD4 lymphocyte percentage below 14% are considered to have AIDS (CMDT 2017).
Methods: This study was continuous longitudinal, prospective and retrospective, observational, at ART plus Centre, Kanpur K.P.S. institute of medicine (G.S.V.M. medical college) included the all patients on ART1 attending in Centre were screened for treatment failure based on clinical, immunological and virological criteria’s as decided by SACEP from 2016 to 2018.
Results: Total numbers of patients are 118 among them 71 female and 47 males, age groups between 30-40 there are 54 patients. In study treatment with ART patients Hb levels more than 10%, Mean value before 10.85±1.31 and mean value after treatment was 10.5±1.31, TLC before 6970.94±6309.93 after treatment 6800.25±2522.99, Serum Bilirubin before and after treatment 0.69±0.49 and 0.95±1.13. Mean value of before and after treatment serum creatinin1.80±11.34 and 0.88±0.38.
Conclusions: There is increased in serum creatinine and SGPT /SGOT and decrease in Hb levels in treatment of second line ART treatment so it should be monitored every monthly interval.
References
Oldfield V, Plosker GL. Lopinavir/ritonavir. A review of its use in the management of HIV infection. Drugs. 2006; 66:1275-99.
Palacios R, Vergara S, Rivero A,Aguilar I, Macías J, Camacho A,et al. Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir. HIV clinical trials. 2006 Dec 1;7(6):319-23.
Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007 Apr 7;369(9568):1169-78.
Fischl MA, Collier AC, Mukherjee AL, Feinberg JE, Demeter LM, Tebas P, et al. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. Aids. 2007 Jan 30;21(3):325-33.
Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. JAIDS. 2007 May 1;45(1):4-8.
Sungkanuparph S, Manosuth W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clinical Infectious Diseases. 2007 Feb 1;44(3):447-52.
Takalkar AA, Saiprasad GS, Prasad VG, Madhekar NS. Study of opportunistic infections in HIV seropositive patients admitted to Community Care Centre (CCC), KIMS Narketpally. Biomed Res. 2012;23(1):139-42
Opeodu O, Ogunrinde TJ. Mode of transmission of hiv/aids: perception of dental patients in a nigerian teaching hospital. J West Afrcoll Surg. 2015;5(1): 1-19.
Jespersen S, Hønge BL, Medina C, da Silva Té D, Correira FG, Laursen AL, et al. Lack of awareness of treatment failure among HIV‐1‐infected patients in Guinea‐Bissau–a retrospective cohort study. J Inter AIDS Soc. 2015 Jan;18(1):20243.
Tsegaye AT, Wubshet M, Awoke T, Alene KA. Predictors of treatment failure on second-line antiretroviral therapy among adults in northwest Ethiopia: a multicentre retrospective follow-up study. BMJ open. 2016 Dec 1;6(12):e012537..
Patel D, Desai M, Shah AN, Dikshit RK. Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients. Perspect Clini Res. 2013 Oct;4(4):215.
Pham MD, Romero L, Parnell B, Anderson DA, Crowe SM, Luchters S. Feasibility of antiretroviral treatment monitoring in the era of decentralized HIV care: a systematic review. AIDS Res Ther. 2017 Dec 1;14(1):3.
Onoya D, Liudmyla KH, Miot BJ, Lawrence C. Long LC, Fox MP. Adverse Drug Reactions Among Patients Initiating Second Line Antiretroviral Therapy in South Africa. Drug Safety. 2018; s40264-018-0698-3.
